"We're proud to have jumped to the top five in this widely-recognised ranking of the world's best science employers. Our excellent researchers around the world are the main source of this company's strong innovation. The fact that they feel respected and take pride in working for a company that operates in a sustainable way is great to see. In the battle to recruit the best researchers, there's nothing more powerful than peer-to-peer communication," says Mads Krogsgaard Thomsen, chief science officer and executive vice president at Novo Nordisk.

R&D professionals at Novo Nordisk comprise world-class experts in the engineering, expression, formulation and delivery of therapeutic proteins, as well as in the development of compounds into safe, effective and convenient treatment options for people living with chronic conditions like diabetes, haemophilia and rheumatoid arthritis. More than 4,000 employees work in Novo Nordisk R&D in Denmark, US, China and India.

"This positive evaluation of Novo Nordisk resonates well with my own personal experience as a diabetes researcher in the company for the past 21 years. Our collaborative work in multidisciplinary teams both within and outside of the company, and our openness to explore new ideas inspire me. It gives me the confidence that I'm part of a highly-qualified team working every day to find better treatment solutions for people with diabetes," says Erica Nishimura, scientific director of Diabetes Biology at Novo Nordisk.

In the Science 2012 survey, 4,276 employees working in the biotechnology, biopharmaceutical, pharmaceutical and related industries were asked to rank the 20 best employers based on 23 characteristics, including research-driven environment and financial strength.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.